Protalix BioTherapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2019
Filed with the SEC on May 6, 2019 and accepted by EDGAR at May 6, 2019, 16:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2019-01-01 to 2019-03-31 | $2.0m | us-gaap:CostOfRevenue |
| Research and development | 3 months2019-01-01 to 2019-03-31 | $11.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2019-01-01 to 2019-03-31 | $2.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-01-01 to 2019-03-31 | −$5.5m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2019-01-01 to 2019-03-31 | −$7.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-01-01 to 2019-03-31 | −$0.05 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2019-01-01 to 2019-03-31 | −$7.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2019-01-01 to 2019-03-31 | $170.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-03-31 | $30.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-03-31 | $47.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-03-31 | $61.0m | us-gaap:Assets |
| Current liabilities | At period end2019-03-31 | $27.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-03-31 | $120.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-03-31 | −$59.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001144204-19-023895. Last ingested by Listed: Nov 10, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.